{"version":"1.0","type":"link","title":"The cost-effectiveness of treatment for high-risk, early-stage, triple-negative breast cancer in Egypt: an analysis of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant single-agent pembrolizumab.","author_name":"Pöllinger B 외","author_url":"https://prs-insight.online/author/P%C3%B6llinger%20B","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/170256","thumbnail_width":1200,"thumbnail_height":630}